Locilex

Locilex™

Cytolex™, MSI-78, pexiganan acetate Infectious disease A topical antibiotic for treating infected diabetic foot ulcers; Locilex is the first in a class of antibiotic/anti-infective magainins, derived from the skin secretions of the African clawed frog, which kill bacteria by attacking cell membranes. See Magainin. Note: It was deemed not approvable.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
(NASDAQ: DPRX) is a late-stage pharmaceutical company focused on the development and commercialisation of Locilex (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, which recently announced that Locilex failed to meet the primary and secondary endpoints in its OneStep-1 and OneStep-2 Phase 3 clinical trials.
Dipexium Closes Merger with Asprin Delivery Specialist PLx Pharma in Stock Deal
M2 PHARMA-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
M2 PHARMA-July 23, 2014-Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium Pharmaceuticals enrols first patient in second of two pivotal Phase III clinical trials for Locilex
Dipexium recently completed its pivotal Phase 3 clinical trials (OneStep-1 and OneStep-2) with Locilex in mild infections of diabetic foot ulcers in the United States under a Special Protocol Assessment (SPA) agreement from the US Food and Drug Administration (FDA).
Dipexium passes EMA's SME designation
M2 EQUITYBITES-February 5, 2016-Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
Dipexium Pharmaceuticals completes 75% enrollment under Pivotal Phase 3 clinical trials of Locilex
M2 EQUITYBITES-October 5, 2015-Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
Dipexium Pharmaceuticals announces 50% enrollment in second pivotal Phase 3 clinical trial of Locilex
Medical browser ?
Full browser ?